These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30931172)

  • 41. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation.
    Ramirez FD; Motazedian P; Jung RG; Di Santo P; MacDonald ZD; Moreland R; Simard T; Clancy AA; Russo JJ; Welch VA; Wells GA; Hibbert B
    Circ Res; 2017 Jun; 120(12):1916-1926. PubMed ID: 28373349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Never too old to fight breast cancer: A case report.
    Zuradelli M; Masci G; Ferraro E; Losurdo A; De Sanctis R; Torrisi R; Santoro A
    Medicine (Baltimore); 2018 Mar; 97(9):e9981. PubMed ID: 29489698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can cancer clinical trials be fixed?
    Allison M
    Nat Biotechnol; 2011 Jan; 29(1):13-5. PubMed ID: 21221090
    [No Abstract]   [Full Text] [Related]  

  • 46. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
    Lewis Phillips GD; Li G; Dugger DL; Crocker LM; Parsons KL; Mai E; Blättler WA; Lambert JM; Chari RV; Lutz RJ; Wong WL; Jacobson FS; Koeppen H; Schwall RH; Kenkare-Mitra SR; Spencer SD; Sliwkowski MX
    Cancer Res; 2008 Nov; 68(22):9280-90. PubMed ID: 19010901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
    Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
    Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanotechnology: Deliver on a promise.
    Wright J
    Nature; 2014 May; 509(7502):S58-9. PubMed ID: 24870822
    [No Abstract]   [Full Text] [Related]  

  • 50. Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort.
    Daniels B; Kiely BE; Tang M; Houssami N; Lord SJ; Pearson SA
    Breast; 2021 Aug; 58():106-112. PubMed ID: 33992964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways.
    Endo Y; Shen Y; Youssef LA; Mohan N; Wu WJ
    MAbs; 2018 Oct; 10(7):1003-1017. PubMed ID: 30130447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.
    Karacin C; Bilgetekin I; Basal FB; Oksuzoglu OB
    J Coll Physicians Surg Pak; 2022 Nov; 32(11):1501-1502. PubMed ID: 36377026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
    Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
    Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
    Boyer JZ; Phillips GDL; Nitta H; Garsha K; Admire B; Kraft R; Dennis E; Vela E; Towne P
    Breast Cancer Res Treat; 2021 Jul; 188(1):65-75. PubMed ID: 34091830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Li C; Wang B; Lu D; Jin JY; Gao Y; Matsunaga K; Igawa Y; Nijem I; Lu M; Strasak A; Chernyukhin N; Girish S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):547-58. PubMed ID: 27423671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
    Noguchi E; Tamura K; Hattori M; Horiguchi J; Sato N; Kanatani K; Matsunaga K; Iwata H; Fujiwara Y
    Breast Cancer; 2019 Jan; 26(1):39-46. PubMed ID: 30039339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
    Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
    Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
    Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.